


10/019,380
~~09/068,240~~



G1 S,N,SO2,C,O,CH2,CH

G2 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s ll

SAMPLE SEARCH INITIATED 13:17:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7686 TO ITERATE

13.0% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

19 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 148469 TO 158971
PROJECTED ANSWERS: 2195 TO 3645

L2 19 SEA SSS SAM L1

=> s ll sss full

FULL SEARCH INITIATED 13:17:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 153476 TO ITERATE

100.0% PROCESSED 153476 ITERATIONS
SEARCH TIME: 00.00.08

3032 ANSWERS

L3 3032 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
148.55	148.76

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:17:50 ON 15 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

Habte

4/11/2003

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Apr 2003 VOL 138 ISS 16
FILE LAST UPDATED: 14 Apr 2003 (20030414/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 673 L3

=> s l4 and antiviral?

L5 15 L4 AND ANTIVIRAL?

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:154225 CAPLUS

DOCUMENT NUMBER: 138:210299

TITLE: Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds

INVENTOR(S): Moro, Daniel G.; Callahan, Howard; Nowotnik, David P.

PATENT ASSIGNEE(S): Access Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015748	A2	20030227	WO 2002-US26083	20020816
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2003044446 A1 20030306 US 2001-931319 20010816

PRIORITY APPLN. INFO.: US 2001-931319 A 20010816

AB The present invention relates to a layered pharmaceutical delivery device for the administration of pharmaceuticals or other active compounds to mucosal surfaces. The device may also be used by itself without the incorporation of a therapeutic. The device of the present invention consists of a water-sol. adhesive layer, a non-adhesive, bioerodible backing layer and one or more pharmaceuticals if desired in either or both layers. Upon application, the device adheres to the mucosal surface, providing protection to the treatment site and localized drug delivery. The "Residence Time", the length of time the device remains on the mucosal surface before complete erosion, can be easily regulated by modifications of the backing layer.


IT 68844-77-9, Astemizole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compds.)

RN 68844-77-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



L5 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:978344 CAPLUS

DOCUMENT NUMBER: 138:44736

TITLE: Taste masking coating composition comprising acrylic polymers, a cellulose ester, and an alkaline modifier

INVENTOR(S): Corbo, Michael; Desai, Jatin; Patell, Mahesh; Warrick, Ronald

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp., Cont.-in-part of U.S. Ser. No. 557,924, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002197317	A1	20021226	US 2002-67724	20020205
US 2000-557924 B2 20000420				


AB There is provided a coating compn. that masks the undesirable taste of a pharmaceutically active ingredient, i.e. drug or medicine, that is taken orally. The coating compn. is comprised of dimethylaminoethyl methacrylate and neutral methacrylic acid ester, a cellulose ester polymer, and an alk. modifier.

IT 68844-77-9, Astemizole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (taste masking coating compn. comprising acrylic polymers, cellulose ester, and alk. modifier)

RN 68844-77-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:888718 CAPLUS

DOCUMENT NUMBER: 137:384842

TITLE: Benzimidazole compounds and antiviral uses

INVENTOR(S): Lackey, John William; Kinder, Daniel S.; Tvermoes, Nicolai A.

PATENT ASSIGNEE(S): Trimeris, Inc., USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092575	A1	20021121	WO 2002-US14598	20020510
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-290038 P 20010511

OTHER SOURCE(S): MARPAT 137:384842

AB Title compds. I [R1, R2 = H, (un)substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl; R3 = H, halo, (un)substituted alkyl, OH, alkoxy, aryl, heterocyclic, heteroaryl; R4-R7 = H, halo, (un)substituted alkyl, OH, alkoxy, aryl, heterocyclic, heteroaryl; X = bond, (un)substituted alkylene, C=N, CO, P, S; Y = N, P, O, S; when Y = O, S, R2 is absent; n = 0-4] were prep. for use as virucides that inhibit membrane fusion assoc. events such as viral transmission, reduce viral load or otherwise treat viral infections, particularly that caused by Respiratory Syncytial Virus. Thus, I [R1 = cyclohexyl, R2 = CHMe2, Y = N, X = CH2, R3 = 2-quinolinyl, R4-R7 = H] had IC50 of 5.16 .mu.g/mL.

IT 475646-87-8P 475646-88-8P 475646-89-8P


475646-90-3P 475646-91-4P 475646-92-5P

475646-93-6P 475646-94-7P 475646-95-8P

475646-96-9P 475646-97-0P 475646-98-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

GI



AB Title compds. I [R1, R2 = H, (un)substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl; R3 = H, halo, (un)substituted alkyl, OH, alkoxy, aryl, heterocyclic, heteroaryl; R4-R7 = H, halo, (un)substituted alkyl, OH, alkoxy, aryl, heterocyclic, heteroaryl; X = bond, (un)substituted alkylene, C=N, CO, P, S; Y = N, P, O, S; when Y = O, S, R2 is absent; n = 0-4] were prep. for use as virucides that inhibit membrane fusion assoc. events such as viral transmission, reduce viral load or otherwise treat viral infections, particularly that caused by Respiratory Syncytial Virus. Thus, I [R1 = cyclohexyl, R2 = CHMe2, Y = N, X = CH2, R3 = 2-quinolinyl, R4-R7 = H] had IC50 of 5.16 .mu.g/mL.

IT 475646-87-8P 475646-88-8P 475646-89-8P

475646-90-3P 475646-91-4P 475646-92-5P

475646-93-6P 475646-94-7P 475646-95-8P


475646-96-9P 475646-97-0P 475646-98-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


Habte

4/11/2003


LS ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (prepn. of benzimidazole deriva. as virucides for treating Respiratory
 Syncytial Virus infections)
 RN 475646-87-8 CAPLUS
 CN 1H-Benzimidazole, 1-[(2-methyl-4-thiazolyl)methyl]-2-(1-piperidinylmethyl)-
 (9CI) (CA INDEX NAME)



RN 475646-88-9 CAPLUS
 CN 1H-Benzimidazole, 1-[(1,1'-biphenyl)-4-ylmethyl]-2-(1-piperidinylmethyl)-
 (9CI) (CA INDEX NAME)




RN 475646-89-0 CAPLUS
 CN 1H-Benzimidazole, 1-(2-methylbenzoyl)-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 475646-90-3 CAPLUS
 CN 1H-Benzimidazole, 1-[(5-nitro-2-furanyl)methyl]-2-(1-piperidinylmethyl)-
 (9CI) (CA INDEX NAME)


LS ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 475646-91-4 CAPLUS
 CN 1H-Benzimidazole, 1-[(2,4-dichlorophenyl)methyl]-2-(1-piperidinylmethyl)-
 (9CI) (CA INDEX NAME)




RN 475646-92-5 CAPLUS
 CN 1H-Benzimidazole, 2-(1-piperidinylmethyl)-1-(2-pyridinylmethyl)- (9CI)
 (CA INDEX NAME)




RN 475646-93-6 CAPLUS
 CN 1H-Benzimidazole, 2-(1-piperidinylmethyl)-1-(3-pyridinylmethyl)- (9CI)
 (CA INDEX NAME)


LS ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 475646-94-7 CAPLUS
 CN 1H-Benzimidazole, 2-(1-piperidinylmethyl)-1-(4-pyridinylmethyl)- (9CI)
 (CA INDEX NAME)



RN 475646-96-9 CAPLUS
 CN 1H-Benzimidazole, 1-[(4-(methylsulfonyl)phenyl)methyl]-2-(1-piperidinylmethyl)-
 (9CI) (CA INDEX NAME)




RN 475646-97-0 CAPLUS
 CN 1H-Benzimidazole, 1-[(4-(methylthio)phenyl)methyl]-2-(1-piperidinylmethyl)-
 (9CI) (CA INDEX NAME)




RN 475646-98-1 CAPLUS
 CN 1H-Benzimidazole, 2-(1-piperidinylmethyl)-1-[(2-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)

LS ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 475646-96-5P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (prepn. of benzimidazole deriva. as virucides for treating Respiratory
 Syncytial Virus infections)

RN 475646-96-5 CAPLUS
 CN 1H-Benzimidazole, 1-(1,2,4-oxadiazol-3-ylmethyl)-2-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Habte

4/11/2003

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002147197	A1	20021010	US 2002-104549	20020320
PRIORITY APPLN. INFO.:			US 1999-158322P	P 19991008
			US 2000-684293	A2 20001006

OTHER SOURCE(S): MARPAT 137:289046

AB Improved methods are provided for therapeutic and/or preventative treatment to a mammal in which the mammal is protected against the toxicity of active pharmaceutical agents that (i) bind to or are substrates for P-gp, (ii) are taxane analogs, and/or (iii) are inhibitors of tubulin disassembly. Addnl. provided are compounds and methods useful for treating cell proliferative disorders. Further provided are methods of increasing the bioavailability of therapeutic and/or preventative treatments in a mammal. Particular embodiments are directed to increasing blood bioavailability across the blood-brain barrier.


IT 68944-77-9, Astemizole 68844-77-9D, Astemizole, derivs., analogs, and metabolites

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods and compns. for enhancing pharmaceutical treatments)

68944-77-9 CAPUS



PN 1H-9H-maleimido-2-amine, 1-[[4-(4-fluorophenyl)methyl]-N-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-3C(1)] CA INDEX NAME



RN 68844-77-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


L5 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:594844 CAPLUS
 DOCUMENT NUMBER: 137:140518
 TITLE: Preparation of thiazolyl-, oxazolyl-, pyrrolyl-, and
 imidazolyl- anionamide derivatives as inhibitors of
 phosphodiesterase IV isozymes
 INVENTOR(S): Macfar, Anthony; McKechney, Michael William
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 249 pp.
 CODEN: PIXXKD
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006998	A1	20020808	WO 2001-182728	20011124
VE:	AG, AE, AL, AM, AT, AU, AZ,	BA, BB, BG, BR, BY,	BZ, CA, CH, CN,	
	CO, CR, CU, CZ, DE, DK, DM,	DZ, EC, EE, EG, ES, FI,	GB, GD, GE, GH, GR,	
	HR, HU, IL, ID, IN, JP,	KE, KG, KP, KR, KZ, LC,	LR, LS, LT, LU, LV, MA, MD,	
	MG, MN, MW, MX, MY, NZ,	OC, OM, PZ, PA, PE, PG,	PH, PI, PK, PL, PT, RO,	
	RU, SD, SE, SG, SI, SK,	SL, SM, ST, TM, TR, TT,	TZ, TD, TG, TH, TJ, TM,	
	UA, US, UZ, VN, YU,	ZA, ZW, AM, AZ, BY, KG,	KZ, MD, RU, RU, TJ, TM,	
RW:	GH, GM, KE, LS, MW, MZ,	SD, SL, SZ, TG, TZ, ZW,	ZW, AT, BE, CH, CY,	
	DE, DK, ES, FI, FR, GB,	GR, IE, IT, LU, MC, NL,	PT, SE, TR, TH, TD, TG,	
	BF, BJ, CF, CG, CI, CM,	CA, GN, GU, GW, HR, HR,	MA, MG, MR, MU, NI, NG,	
US 2002123520	A1	20020905	US 2002-62145	20020131
US 200123520		US	2001-265486P	20010131
PRIORITY AFFILN. INFO:				
OTHER SOURCE(S):		MAPPAT 137:140518		
G1				



Habte


15 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



15 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

AB Title compds. I [wherein p = -O-, q = -O-; provided that when q = O, n = 2; m = 0-3; n = 1-4; V1 and V2 independently O, SOO-2, or NR3; or W = (un)substituted ethyl, propyl, or butyl; Y = SOO-2, O, NOO-1, NR3, or (un)substituted methylene; R A and RB = independently H, F, CF₃, alkyl, or (un)substituted cycloalkyl, Ph, or benzyl; or when m = 1, CRABR = (un)substituted spiro; RC and RD have the same meaning as RA and RB except that one of them must be H; RI and RV = R, F, Cl, CN, NO₂, (fluoro)alkyl, alkenyl, alkynyl, phenoxy, phenyl, carbamoyl, ureido, (hetero)aryl, etc.; R₂ = H, alkyl, Ph, benzyl, alkenyl, phenyl, etc.; R₄, R₅, and R₆ = H, F, Cl, and (un)substituted (cyclo)alkyl, alkenyl, alkynyl, Ph, benzyl, pyridyl, alkoxy, phenoxy, acyl, carboxy, CN, NO₂, carbamoyl, ureido, (hetero)aryl, etc.; G1 and G2 = independently (un)satd. carbocyclyl or heterocyclyl;] Example, 1-(3-cyanophenoxymethyl)thiazole-5-carboxylic acid was treated with 2-(4-aminomethylphenyl)propan-2-ol in the presence of EDCI and HOBT in DMF to give the thiazolamide II. I are useful in the treatment of diseases regulated by the activation and degradation of intracellular signaling molecules, esp. asthma, chronic bronchitis, allergic rhinitis, obstructive pulmonary disease (no data). In addition, I may be used in combination therapy with a wide variety of other therapeutic agents.

IT	68844-77-9, Aztemizole	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination therapy with PD54 inhibitors: prepn. of thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl- acid amide derivs. as inhibitors of PD54 isoenzymes)
RN	68844-77-9 CAPLUS	
CN	1H-Benzimidazol-2-amine, 1-[4-(4-fluorophenyl)methyl]-N-1-[2-(4-methylpiperidin-1-yl)ethyl]-4-piperidinyl)- (9CI) (CA INDEX NAME)	



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:594842 CAPLUS

DOCUMENT NUMBER: 137:154859

TITLE: Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes

INVENTOR(S): Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 285 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060896	A1	20020808	WO 2001-182726	20011224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003027845	A1	20030206	US 2002-66503	20020131
PRIORITY APPLN. INFO.: MARPAT 137:154859				
OTHER SOURCE(S):				
GI				

LS ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)-2, or NR3; Y = =C(R1a) or N(O)-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl, Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F, Cl, alkynyl, R16, OR16, SOO-2R16, COR16, CO2R16, OCO16, CN, NO2, (un)substituted carbamoyl, ureido, carbamimidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd. monocyclic or fused polycyclic ring; D = (un)substituted carbonyl, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl were prepd. as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yl)nicotinic acid was coupled with 4-aminomethyl-3-fluorophenylacetic acid to give the pyridinecarboxamide II ethylcarbamodimide.bul.HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Sapon. using aq. LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.


LS ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

IT 68844-77-9, Astemizole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination therapy with PDE4 inhibitors; prepn. of carbamoyl-substituted pyridinyl aryl ether derivs. as inhibitors of PDE4 isoenzymes)

RN 68844-77-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:594822 CAPLUS

DOCUMENT NUMBER: 137:154857

TITLE: Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4 isozymes

INVENTOR(S): Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 224 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060875	A1	20020808	WO 2001-182341	20011206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002193612	A1	20021219	US 2001-265492P	20010131
PRIORITY APPLN. INFO.: MARPAT 137:154857				
OTHER SOURCE(S):				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I: g = 0-1; j = 0-1; provided that when j = 0, n must be 2; k = 0-1; m = 0-2; n = 1-2; W1 = 0, SOT (t = 0-2), NR3; W2 = OCR9R10, or absent; Y = CR1, NOK (k = 0-1); R9, R10 = H, F, CF3, etc.; or R9 and R10 are taken together, but only in the case where m = 1, to form a spiro moiety; R7, R8 have the same meaning as R9, R10 except that one of them must be H; R1, R2 = H, F, Cl, etc.; R3 = H, alkyl, Ph, etc.; R4-R6 = H, F, Cl, etc.; Q1 = Ph, benzodioxyl, etc.; Q2 = biaryl moiety, useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease, were prepd. E.g., a multi-step synthesis of the amide II, starting from Me 3-bromobenzoate and 4-formylbenzenesboronic acid, was given. Compds. I showed anti-inflammatory activity at 0.0001 .mu.M to 20.0 .mu.M in whole blood assay for LTR4.


IT 68844-77-9, Astemizole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (in combination with; prepn. of biaryl nicotinamides as inhibitors of PDE4 isoenzymes)

RN 68844-77-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:591707 CAPLUS
DOCUMENT NUMBER: 137:140509
TITLE: Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes
INVENTOR(S): Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 180 pp.
CODEN: EPXKDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1229034	A1	20020807	EP 2002-250202	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002111495	A1	20020815	US 2002-62811	20020131
BR 2002000250	A	20021008	BR 2002-250	20020131
PRIORITY APPLN. INFO.:			US 2001-265240P	P 20010131
			US 1997-43403P	P 19970404
			US 1998-105120P	P 19981021


OTHER SOURCE(S): MARPAT 137:140509
G1



AB Title compds. [I: p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; V = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkenyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkenyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with proviso], were prepd. (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yl)oxy]pyridine-3-2-[4-[[[2-(benzo[1,3]dioxol-5-yl)oxy]phenyl]-2-methylpropionate was suspended in Me3COH. carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Ac. NaOH was added to the suspension, and the reaction mixt. was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yl)oxy]pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

IT 68844-77-9, Astemizole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

L5 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 68844-77-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:838793 CAPLUS
DOCUMENT NUMBER: 137:57492
TITLE: Blood donors on medication: are deferral periods necessary?
AUTHOR(S): Stichenoeth, Dirk O.; Deicher, Helmut R. G.; Frolich, Jurgen C.
CORPORATE SOURCE: Institute of Clinical Pharmacology, Medizinische Hochschule Hannover, Hannover, 30623, Germany
SOURCE: European Journal of Clinical Pharmacology (2001), 57(6-7), 433-440
CODEN: EUCPAS; ISSN: 0031-6970
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Drugs and their metabolites in transfused blood components may cause effects in the recipient. If the disorder being treated is not to be regarded as an exclusion criterion from blood donation, donors on medication should be deferred for a period consistent with the drug's pharmacokinetics. Peak plasma drug concns. of .ltoreq.3% of the therapeutic concn. were regarded to be safe for the recipient of a blood product. For teratogenic drugs a much lower safety level of <0.000001% has been proposed. For the calcn. of deferral periods, both the type of blood component to be prepd. and the drug's pharmacokinetics were considered. For drugs with known teratogenic risks, a deferral period of 28 plasma-elimination half-lives is suggested. For nonteratogenic drugs, a simple, conservative approach could be based on waiting for 5 plasma-elimination half-lives, thus reaching the required 3% safety level. If, however, the type of blood component to be prepd. is also considered, a more differentiated approach appears to be appropriate: for blood components contg. .ltoreq.50 mL plasma from a single donor, donor components may be disregarded because of the high diln. in the recipient's plasma vol., whereas for blood components with higher plasma contents (250 mL on av.) from a single donor on medication the 3% safety level will be achieved by observing the deferral period of 5 plasma-elimination half-lives. A guideline for 191 drugs and drug classes is presented.

IT 68844-77-9, Astemizole
RL: ADV (Adverse effect, including toxicity); BUU (Biological use, unclassified); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(waiting period before transfusion of blood products prepd. from blood of humans taking various drugs, including)

RN 68844-77-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

4/11/2003

Habte

L5 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

L5 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:798029 CAPLUS
 DOCUMENT NUMBER: 135:348884
 TITLE: Taste masking coating compositions containing polymers
 INVENTOR(S): Corbo, Michael; Desai, Jatin; Patell, Mahesh; Warrick, Ronald
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080829	A2	20011101	WO 2001-US12805	20010419
WO 2001080829	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1276469 A2 20030122 EP 2001-928678 20010419
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR


PRIORITY APPLN. INFO.:
 US 2000-553513 A 20000420
 WO 2001-US12805 W 20010419

AB There is provided a coating compn. that masks the undesirable taste of an active ingredient, i.e. drug or that is consumed orally. The coating compn. has polyvinyl acetate, and a dimethylaminoethyl methacrylate and neutral methacrylic acid ester. Optionally, an alk. modifier may be included in the coating compn. to enhance release of the active ingredient. Coating (A) made of Kolli-don-SR 27.78, 27.8 Et cellulose 7, Eudragit E-100 28.0, Eastman 9-45 (Acetylated Monoglyceride) 11.44, and talc 51 was applied to a drug ingredient, such as granules of acetaminophen (APAP) or caffeine powder. The coated drug ingredient was then compressed into tablets, that were then subjected to dissoln. testing in solns. having a pH of 7 and 1.2. Dissoln. was hindered by coating (A), in an environment where the pH was about 7, and dissoln. was quicker in an environment where the pH was about 1.2. The coating compn. of the inhibited the availability of the drug ingredient and thereby provided an effective means for masking the undesirable taste of a drug ingredient such as APAP or caffeine under neutral pH conditions.

IT
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (taste masking coating compns. contg. polymers)

RN 68844-77-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



L5 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:798026 CAPLUS
 DOCUMENT NUMBER: 135:348884
 TITLE: Taste masking coating composition based on methacrylate polymer and cellulose ester
 INVENTOR(S): Corbo, Michael; Desai, Jatin; Patell, Mahesh; Warrick, Ronald
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080826	A2	20011101	WO 2001-US12709	20010418
WO 2001080826	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1276470 A2 20030122 EP 2001-930585 20010418
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR


PRIORITY APPLN. INFO.:
 US 2000-557924 A 20000420
 WO 2001-US12709 W 20010418

AB There is provided a coating compn. that masks the undesirable taste of a pharmaceutically active ingredient, i.e. drug or medicine, that is taken orally. The coating compn. has a dimethylaminoethyl methacrylate and neutral methacrylic acid ester, a cellulose ester polymer, and an alk. modifier, e.g. triethanolamine. For example, acetaminophen in the crystal form having a mesh size about 40 to 80, was coated with a coating compn. of 60% cellulose acetate/28% Eudragit E 100/12% triethanolamine. The same coating compn. was applied as a coating for granular caffeine that was also about 40 to 80 mesh size. The coating thickness was varied and the coated crystals and granules were formed into tablets.

IT
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (taste masking coatings for oral compns. based on blend of methacrylate polymer and cellulose esters)

RN 68844-77-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


L5 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:12445 CAPLUS
 DOCUMENT NUMBER: 134:86249
 TITLE: Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.
 INVENTOR(S): Janssens, Frans Eduard; Meersman, Kathleen Petrus; Marie-Jose Sommen, Francois Maria; Andries, Koenraad; Jozef Lodewijk Marcel
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000612	A2	20010104	WO 2000-EP5675	20000620
WO 2001000612	A3	20010329		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012047	A2	20020312	BR 2000-12047	20000620
EP 1196409	A	20020417	EP 2000-943840	20000620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003503402	T2	20030128	JP 2001-507021	20000620
NO 2001006369	A	20020220	NO 2001-6369	20011227
PRIORITY APPLN. INFO.: EP 1999-202088 A 19990628 WO 2000-EP5675 W 20000620				
OTHER SOURCE(S): MARPAT 134:86249				
GI				



AB Title compds. I: {a1:a2:a3:a4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, CH:CHCH:N; Q = R2R4NAX1, R2R4NCOAX1, specified (substituted) (heterocyclyl); A = (substituted) alkanediyl; X1 = imino, S, SO, SO2, O, CH2, CO, CH(OH), etc.; R1 = (substituted) monocyclic


L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

heterocyclyl, aryl; R2 = H, formyl, alkylcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, cycloalkyl, substituted alkyl; R4 = H, alkyl, aralkyl, were preps. Thus, 1-[ethoxy(2-pyridinyl)methyl]-N-[1-alkyl, aralkyl]-1H-benzimidazol-2-amine was hydrogenated in (phenylmethyl)-4-piperidinyl-1H-benzimidazol-2-amine in MeOH over Pd/C to give 1-[ethoxy(2-pyridinyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine. Tested I inhibited respiratory syncytial virus replication with IC50 = 0.00032-1.2589 .mu.M.

IT 317384-42-2P 317384-43-3P 317384-46-6P
 317384-47-7P 317384-48-8P 317384-49-9P
 317384-50-2P 317384-51-3P 317384-52-4P
 317384-55-7P 317384-56-8P 317384-57-9P
 317384-58-0P 317384-59-1P 317384-60-4P
 317384-61-5P 317384-62-6P 317384-63-7P
 317384-65-9P 317384-66-0P 317384-67-1P
 317384-68-2P 317384-69-3P 317384-70-6P
 317384-71-7P 317384-72-8P 317384-73-9P
 317384-74-0P 317384-75-1P 317384-76-2P
 317384-77-3P 317384-78-4P 317384-79-5P
 317384-80-8P 317384-81-9P 317384-82-0P
 317384-83-1P 317384-84-2P 317385-29-8P
 317385-30-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of benzimidazoles as respiratory syncytial virus replication inhibitors)

RN 317384-42-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-methoxyethoxy)(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 317384-43-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-chloro-1-[(2-methoxyethoxy)(6-methyl-2-pyridinyl)methyl]-4-methyl-, trihydrochloride, trihydrate (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




● 3 HCl

RN 317384-46-6 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(6-bromo-2-pyridinyl)ethoxymethyl]- (9CI) (CA INDEX NAME)




RN 317384-47-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 317384-48-8 CAPLUS

4/11/2003

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-methoxyethoxy)(6-methyl-2-pyridinyl)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 317384-49-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-ethoxyethoxy)(6-phenyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 317384-50-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-methoxyethoxy)(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
 NAME)




● 3 HCl

RN 317384-56-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[(6-bromo-2-pyridinyl)ethoxymethyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 317384-57-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-(ethoxy-2-pyridinylmethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 317384-58-0 CAPLUS
 CN 1H-Benzimidazole-1-ethanol, .alpha.-(4-chlorophenyl)-2-(4-piperidinylamino)- (9CI) (CA INDEX NAME)

Habte

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317384-51-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(6-bromo-2-pyridinyl)ethoxymethyl]-4-methyl-, monohydrate (9CI) (CA INDEX NAME)




● H2O

RN 317384-52-4 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-(2-methoxy-2-phenylethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 317384-55-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[ethoxy[6-methyl-3-(phenylmethoxy)-2-pyridinyl)methyl]-N-4-piperidinyl-, trihydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317384-59-1 CAPLUS
 CN Carbamic acid, [2-[4-[[1-[(6-bromo-2-pyridinyl)ethoxymethyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 317384-60-4 CAPLUS
 CN Carbamic acid, [1-[[4-[[1-[(6-bromo-2-pyridinyl)ethoxymethyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]methyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 317384-61-5 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[ethoxy[6-methyl-3-(phenylmethoxy)-2-pyridinyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)


4/11/2003

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 3 HCl


RN 317384-62-6 CAPLUS
CN Ethanol, 2-[[1-[(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl] (6-methyl-2-pyridinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 317384-63-7 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-ethoxyethoxy) (6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 317384-68-2 CAPLUS
CN 1H-Benzimidazole-1-ethanol, .alpha.-(2-fluorophenyl)-2-(4-piperidinylamino)- (9CI) (CA INDEX NAME)




RN 317384-69-3 CAPLUS
CN 1H-Benzimidazole-1-ethanol, .alpha.-(4-methylphenyl)-2-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 317384-70-6 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(R)-ethoxy(6-methyl-2-pyridinyl)methyl]-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




RN 317384-71-7 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(R)-ethoxy(6-methyl-2-pyridinyl)methyl]-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.

Habe


L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317384-65-9 CAPLUS
CN 1H-Benzimidazole-1-ethanol, .alpha.-(3-methylphenyl)-2-(4-piperidinylamino)- (9CI) (CA INDEX NAME)




RN 317384-66-0 CAPLUS
CN 1H-Benzimidazole-1-ethanol, .alpha.-(3-methoxyphenyl)-2-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 317384-67-1 CAPLUS
CN 1H-Benzimidazole-1-ethanol, .alpha.-(3-fluorophenyl)-2-(4-piperidinylamino)- (9CI) (CA INDEX NAME)




L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317384-72-8 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(S)-ethoxy(6-methyl-2-pyridinyl)methyl]-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




RN 317384-73-9 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(R)-6-bromo-2-pyridinyl]ethoxymethyl]-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


4/11/2003

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317384-74-0 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(S)-(6-bromo-2-pyridinyl)ethoxymethyl]-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 317384-75-1 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(S)-(6-bromo-2-pyridinyl)ethoxymethyl]-, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317384-76-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(S)-(6-bromo-2-pyridinyl)ethoxymethyl]-, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 317384-77-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(S)-(6-methyl-2-pyridinyl)ethoxymethyl]-, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317384-78-4 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-aminopropyl]-4-piperidinyl]-1-[(R)-ethoxy(6-methyl-2-pyridinyl)methyl]-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 317384-79-5 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-aminopropyl]-4-piperidinyl]-1-[(S)-ethoxy(6-methyl-2-pyridinyl)methyl]-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317384-80-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-aminopropyl]-4-piperidinyl]-1-[(R)-ethoxy(6-methyl-2-pyridinyl)methyl]-, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.




RN 317384-81-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-aminopropyl]-4-piperidinyl]-1-[(S)-ethoxy(6-methyl-2-pyridinyl)methyl]-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317384-82-0 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(6-bromo-2-pyridinyl)ethoxymethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 317384-83-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2-amino-3-methylbutyl)-4-piperidinyl]-6-chloro-1-[(2-methoxyethoxy)(6-methyl-2-pyridinyl)methyl]-4-methyl-, trihydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317385-30-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(5S)-ethoxy(6-methyl-2-pyridinyl)methyl]-, monohydrate, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 317385-03-8 317385-04-9 317385-05-0
317385-06-1 317385-10-7 317385-12-9
317385-13-0 317385-14-1 317385-31-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of benzimidazoles as respiratory syncytial virus replication inhibitors)


RN 317385-03-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[2-hydroxy-2-(6-methyl-2-pyridinyl)ethyl]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 3 HCl

RN 317384-84-2 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2-amino-3-methylbutyl)-4-piperidinyl]amino]-.alpha.-(6-methyl-2-pyridinyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl


RN 317385-29-8 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2R)-2-amino-3-methylbutyl]-4-piperidinyl]-1-[(R)-ethoxy(6-methyl-2-pyridinyl)methyl]-, monohydrate, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317385-04-9 CAPLUS
CN Ethanone, 1-(4-methylphenyl)-2-[2-(4-piperidinylamino)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 317385-05-0 CAPLUS
CN Ethanone, 1-(3-methoxyphenyl)-2-[2-(4-piperidinylamino)-1H-benzimidazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 317385-06-1 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[ethoxy(6-methyl-2-pyridinyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)


L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317385-10-7 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-(ethoxy-2-pyridinylmethyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 317385-12-9 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(6-methyl-2-pyridinyl)[2-(phenylmethoxy)ethoxymethyl]- (9CI) (CA INDEX NAME)




RN 317385-13-0 CAPLUS
CN 2-Butanone, 1-[4-[[1-[(2-ethoxyethoxy)(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)


L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

IT 317384-85-3P 317384-86-4P 317384-87-5P
317384-88-6P 317384-93-3P 317384-94-4P
317384-98-8P 317385-00-5P 317385-01-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzimidazoles as respiratory syncytial virus replication inhibitors)


RN 317384-85-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[2-(4-chlorophenyl)-2-oxoethyl]-1H-benzimidazol-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 317384-86-4 CAPLUS
CN Ethanone, 1-(4-chlorophenyl)-2-[2-(4-piperidinylamino)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 317384-87-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[2-(hydroxy-2-phenylethyl)-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317384-88-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[2-(methoxy-2-phenylethyl)-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317385-14-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[2-(hydroxy-2-phenylethyl)-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 317385-31-2 CAPLUS
CN Carbamic acid, [2-[4-[[1-[2-(hydroxy-2-phenylethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317384-93-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[2-(hydroxy-2-phenylethyl)-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317384-94-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[2-(hydroxy-2-phenylethyl)-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317384-98-8 CAPLUS

4/11/2003

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 2-Propanone, 1-[4-[[1-[ethoxy(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 317385-00-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[1-[[6-(dimethylamino)-2-pyridinyl]ethoxymethyl]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317385-01-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[1-[[6-(aminocarbonyl)-2-pyridinyl]ethoxymethyl]-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:12444 CAPLUS
 DOCUMENT NUMBER: 134:86248
 TITLE: Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.
 INVENTOR(S): Janssens, Frans Eduard; Meersman, Kathleen Petrus Marie-Jose; Sommen, Francois Maria; Guillemonet, Jerome Emile Georges; Lacrampe, Jean Fernand Armand; Andries, Koenraad Jozef Lodevijk Marcel
 Janssen Pharmaceutica N.V., Belg.
 PATENT ASSIGNEE(S): PCT Int. Appl., 119 pp.
 SOURCE: CODEN: FIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000611	A1	20010104	WO 2000-EP5676	20000620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012054	A	20020319	BR 2000-12054	20000620
EP 1196408	A1	20020417	EP 2000-943841	20000620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003503401	T2	20030128	JP 2001-507020	20000620
EE 200100692	A	20030217	EE 2001-692	20000620
NO 2001006368	A	20020228	NO 2001-6368	20011227
PRIORITY APPL. INFO.: EP 1999-202087 A 19990628				
EP 2000-200452 A 20000211				
WO 2000-EP5676 W 20000620				


OTHER SOURCE(S): MARPAT 134:86248
 GI



AB Use of title compds. [1: a1:a2:a3:a4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:R:CH:CH, CH:CHCH:CH, CH:CHCH:CH, N:R2R4NAX1, R2R4NCOAX1, specified (heterocyclic) ring, etc.; A = alkylene; R2 = H, CHO, alkylcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, aminocycloalkyl, etc.; R4 = H, alkyl, aralkyl; G = bond, alkanediyl; R1 = (substituted) piperidinyl, alkyl, aralkyl, furanyl, thiophenyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, etc.] for treatment of viral infection is claimed. Thus, 1,1-dimethylethyl 4-[[1-[[3,5-dihydro-3,3-

Hahte


L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
 dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-ylmethyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate was refluxed 6 h in 10N HCl to give 4-[[1-[[3,5-dihydro-3,3-dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-yl]methyl]-1H-benzimidazol-2-yl]amino]piperidine. Tested 1 inhibited respiratory syncytial virus replication with IC50 = 0.00013-2.5119 .mu.M.

IT 317846-43-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of benzimidazoles as respiratory syncytial virus replication inhibitors)

RN 317846-43-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-4-piperidinyl-1-(2-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


IT 317846-01-8P 317846-03-0P 317846-04-1P
 317846-05-2P 317846-06-3P 317846-07-4P
 317846-08-5P 317846-09-6P 317846-10-9P
 317846-11-0P 317846-12-1P 317846-13-2P
 317846-14-3P 317846-15-4P 317846-16-5P
 317846-17-6P 317846-18-7P 317846-19-8P
 317846-20-1P 317846-21-2P 317846-22-4P
 317846-24-5P 317846-25-6P 317846-26-7P
 317846-27-8P 317846-28-9P 317846-29-0P
 317846-30-3P 317846-31-4P 317846-32-5P
 317846-33-6P 317846-34-7P 317846-35-8P
 317846-36-9P 317846-38-1P 317846-39-2P
 317846-41-6P 317846-42-7P 317846-44-9P
 317846-45-0P 317846-46-1P 317846-47-2P
 317846-48-3P 317846-49-4P 317846-50-7P
 317846-51-8P 317846-52-9P 317846-53-0P
 317846-54-1P 317846-55-2P 317846-56-3P
 317846-57-4P 317846-58-5P 317846-59-6P
 317846-60-9P 317846-61-0P 317846-62-1P
 317846-63-2P 317846-64-3P 317846-65-4P
 317846-66-5P 317846-67-6P 317846-68-7P
 317846-69-8P 317846-70-1P 317846-71-2P
 317846-72-3P 317846-73-4P 317846-74-5P
 317846-75-6P 317846-76-7P 317846-77-8P
 317846-78-9P 317846-79-0P 317846-80-3P
 317846-81-4P 317846-82-5P 317846-83-6P
 317846-84-7P 317846-85-8P 317846-86-9P
 317846-89-2P 317846-91-6P 317846-92-7P

4/11/2003


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

317846-93-8P 317846-94-9P 317846-95-1P
317846-97-2P 317846-98-3P 317846-99-4P
317847-00-0P 317847-01-1P 317847-02-2P
317847-03-3P 317847-04-4P 317847-05-5P
317847-06-6P 317847-07-7P 317847-08-8P
317847-11-3P 317847-12-4P 317847-13-5P
317847-14-6P 317847-15-7P 317847-16-8P
317847-17-9P 317847-18-0P 317847-19-1P
317847-20-4P 317847-21-5P 317847-22-6P
317847-23-7P 317847-26-0P 317847-27-1P
317847-28-2P 317847-29-3P 317847-31-7P
317847-32-8P 317847-33-9P 317847-35-1P
317847-36-2P 317847-85-1P 317847-94-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BLOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazoles as respiratory syncytial virus replication inhibitors)

RN 317846-01-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(6-methylpyrazinyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 317846-03-0 CAPLUS
CN Ethanol, 2-[(6-methyl-2-[(2-(4-piperidinylamino)-1H-benzimidazol-1-yl)methyl]-3-pyridinyl)oxy]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 317846-04-1 CAPLUS


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Benzimidazole, 2-[(hexahydro-1H-azepin-4-yl)methyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 317846-08-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 6-[(2-(4-piperidinylamino)-1H-benzimidazol-1-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 317846-09-6 CAPLUS
CN Carbamic acid, [2-[4-[(1-[(6-methylpyrazinyl)methyl]-1H-benzimidazol-2-yl)amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 317846-10-9 CAPLUS
CN Carbamic acid, [2-[4-[(1-[(2-(1,1-dimethylethyl)-1,6-dihydro-6-oxo-4-pyrimidinyl)methyl]-1H-benzimidazol-2-yl)amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Habte

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 3,4-Pyridinedimethanol, 5-hydroxy-6-[[2-(4-piperidinylamino)-1H-benzimidazol-1-yl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 317846-05-2 CAPLUS
CN 1H-Benzimidazol-2-amine, N-(hexahydro-1H-azepin-4-yl)-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-06-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[(6-methyl-2-pyridinyl)methyl]-2-(4-piperidinylamino)-, ethyl ester (9CI) (CA INDEX NAME)




RN 317846-07-4 CAPLUS


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317846-11-0 CAPLUS
CN Carbamic acid, [2-[4-[(1-[(3-(2-chloroethoxy)-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl)amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 317846-12-1 CAPLUS
CN Carbamic acid, [2-[4-[(1-[(3-[2-(dimethylamino)ethoxy]-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl)amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317846-13-2 CAPLUS
CN Carbamic acid, [2-[4-[(1-[(6-chloro-3-pyridazinyl)methyl]-1H-benzimidazol-2-yl)amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


4/11/2003

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Acetamide, N-[2-{{trans-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]cyclohexyl}amino]ethyl}- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 317846-14-3 CAPLUS
 CN Carbamic acid, [2-[4-[[1-(3-pyridazinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317846-15-4 CAPLUS
CN Acetamide, N-[2-[[[cis-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 317846-16-5 CAPLUS



RN 317846-17-6 CAPLUS
CN Carbamic acid, [1,1-dimethyl-2-{4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl}ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317846-18-7 CAPLUS
CN Carbamic acid, [2-[4-[[6-amino-1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 317846-19-8 CAPLUS
 CN Formamide, N-[2-[4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 317846-20-1 CAPLUS
CN Carbamic acid, [1-(hydroxymethyl)-2-{4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinylethyl}-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 317846-21-2 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride (9CI) (CA INDEX NAME)



●4 HCl


RN 317846-23-4 CAPLUS
Butenedioic acid, compd. with 2-[[2-[[1-(2-aminoethyl)-4-

Habte

15 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl)methyl]-6-methyl-3-
pyridinol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 317846-22-3
CMF C22 H30 N6 O



CM 2


CRN 110-15-6
CMF C4 H6 O4

$$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$$

RN 317846-24-5 CAPLUS
CN Butanedioic acid, hydroxy-, compd. with 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-oxindolinol (1:1) (9CI) (CA INDEX NAME)

CH 1


CRN 317846-22-3
CMF C22 H30 N6 O




CH 2

4/11/2003


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CNU 6915-15-7
 CNF C4 H6 O5



RN 317846-25-6 CAPLUS
 CN Formamide, N-[2-[4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-4-methyl-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 317846-26-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(1,5-dimethyl-1H-pyrrol-2-yl)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 317846-27-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-4-methyl-1-[3-(2-pyridinyl)propyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317846-31-4 CAPLUS
 CN 3-Pyridinol, 2-[[2-[[1-(2-amino-3-methylbutyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 317846-32-5 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-chloro-1,4-dimethyl-1H-imidazol-5-yl)methyl]- (9CI) (CA INDEX NAME)



RN 317846-33-6 CAPLUS
 CN Ethanol, 2-[[2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinyl]oxy]-, trihydrochloride (9CI) (CA INDEX NAME)


Habte

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




● 4 HCl

RN 317846-28-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[1-(aminomethyl)propyl]-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 317846-29-0 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-30-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




● 3 HCl

RN 317846-34-7 CAPLUS
 CN 3,4-Pyridinedimethanol, 6-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-5-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 317846-35-8 CAPLUS
 CN 1,4-Piperidinediamine, N4-(2-aminoethyl)-N1-[1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




4/11/2003


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 317846-36-9 CAPLUS
 CN Ethanol, 2-[[2-[4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 317846-38-1 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-1-methylethyl)-4-piperidinyl]-1-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 317846-39-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(4-aminobutyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-41-6 CAPLUS
 CN 1-Piperidineethanol, .alpha.-(aminomethyl)-4-[[4-methyl-1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 3 HCl


RN 317846-46-1 CAPLUS
 CN 1-Piperidinepropanol, .beta.-amino-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl

RN 317846-47-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(1R,2R)-2-amino-1,2-diphenylethyl]-4-piperidinyl]-1-(2-pyridinylmethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 317846-48-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(1R,2S)-2-amino-1,2-diphenylethyl]-4-piperidinyl]-1-(2-pyridinylmethyl)-, rel- (9CI) (CA INDEX NAME)

Habte

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317846-42-7 CAPLUS
 CN 1-Piperidineethanaminium, N,N,N-trimethyl-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-, iodide (9CI) (CA INDEX NAME)



● 1-

RN 317846-44-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(1-aminocyclopropyl)methyl]-4-piperidinyl]-1-(2-pyridinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl


RN 317846-45-0 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-2-methylpropyl)-4-piperidinyl]-1-(2-pyridinylmethyl)-, trihydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)


Relative stereochemistry.



RN 317846-49-4 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminocyclohexyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-50-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(1-aminomethyl)-2-phenylethyl]-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-51-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[(1-aminomethyl)-2,2-dimethylpropyl]-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

4/11/2003


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317846-52-9 CAPLUS
CN 1,3-Propanediamine, N,N-dimethyl-2-[4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 317846-53-0 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-2-phenylethyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-54-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-2-cyclohexylethyl)-4-piperidinyl]-1-(2-pyridinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317846-58-5 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-2-cyclohexylethyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-59-6 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-1-methylpropyl)-4-piperidinyl]-1-(2-pyridinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)



●4 HCl


RN 317846-60-9 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-4-methylpentyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




●4 HCl

RN 317846-55-2 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-2-cyclopropylethyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-56-3 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-1-methylpropyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-57-4 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-4-methylpentyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317846-61-0 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-5-methylhexyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 317846-62-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-5-methylhexyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-63-2 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminopentyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 317846-64-3 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminodecyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 317846-65-4 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-4-phenylbutyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-66-5 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-4,4-dimethylpentyl)-4-piperidinyl]-1-(2-pyridinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl


RN 317846-67-6 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2R,3R)-2-amino-3-methylpentyl]-4-

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
piperidinyl]-1-(2-pyridinylmethyl)-, pentahydrochloride (9CI) (CA INDEX NAME)




● 5 HCl

RN 317846-71-2 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-1-methylethyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 317846-72-3 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-3-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-73-4 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(3-aminopropyl)-4-piperidinyl]-1-(2-pyridinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)




L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
piperidinyl]-1-(2-pyridinylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 317846-68-7 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-[(2R,3S)-2-amino-3-methylpentyl]-4-piperidinyl]-1-(2-pyridinylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 317846-69-8 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-4-(4-methoxyphenyl)butyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-70-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-2-(4-piperidinyl)ethyl)-4-

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




● 4 HCl

RN 317846-74-5 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-(dimethylamino)ethyl)-4-piperidinyl]-1-(2-pyridinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl

RN 317846-75-6 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminopropyl)-4-piperidinyl]-1-[(5-methylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 317846-76-7 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminopropyl)-4-piperidinyl]-1-[(6-methylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317846-77-8 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminopropyl)-4-piperidinyl]-1-[(trimethylpyrazinyl)methyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)




●4 HCl

RN 317846-78-9 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(trimethylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317846-79-0 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminopropyl)-4-piperidinyl]-1-[(2-pyridinyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 317846-80-3 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(6-methylpyrazinyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




●3 HCl

RN 317846-81-4 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 317846-82-5 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(3,4-dimethoxy-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 317846-83-6 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[[[2-[(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317846-84-7 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(3,4-dimethoxy-2-pyridinyl)methyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)



●4 HCl

RN 317846-85-8 CAPLUS
CN Benzenesulfonamide, N-[2-[[[2-[(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-6-chloro-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 317846-87-0 CAPLUS


4/11/2003

Habte

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-
 [(5,6-dimethoxy-2-pyridinyl)methyl]-, ethanedioate (2:7) (9CI) (CA INDEX
 NAME)

CM 1

CRN 317846-86-9
 CMF C25 H36 N6 O2



CM 2


CRN 144-62-7
 CMF C2 H2 O4




RN 317846-89-2 CAPLUS
 CN 1H-Azepine-1-ethanamine, hexahydro-4-[[1-(2-pyridinylmethyl)-1H-
 benzimidazol-2-yl]methyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 317846-88-1
 CMF C22 H29 N5




L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




● 4 HCl

RN 317846-93-8 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-methyl-3-
 furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 317846-94-9 CAPLUS
 CN 1,4-Cyclohexanediamine, N-(2-aminoethyl)-N'-[1-(2-pyridinylmethyl)-1H-
 benzimidazol-2-yl]-, tetrahydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 4 HCl

RN 317846-96-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[1-[(3-amino-2-pyridinyl)methyl]-1H-
 benzimidazol-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 317846-91-6 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)hexahydro-1H-azepin-4-yl]-1-(2-
 pyridinylmethyl)-, ethanedioate (2:7) (9CI) (CA INDEX NAME)

CM 1

CRN 317846-90-5
 CMF C21 H28 N6




CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 317846-92-7 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[1-[2-(methylamino)ethyl]-4-piperidinyl]-1-(2-
 pyridinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317846-97-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[4-(2-amino-3-methylbutyl)-1-piperazinyl]-1-(2-
 pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317846-98-3 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[4-(2-aminoethyl)-1-piperazinyl]-1-(2-
 pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 317846-99-4 CAPLUS
 CN 3-Pyridinol, 2-[[[1-[(2-amino-3-methylbutyl)-4-piperidinyl]amino]-7-
 methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride,
 monohydrate (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 4 HCl


● H₂O

RN 317847-00-0 CAPLUS
CN 3-Pyridinol, 2-[[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 317847-01-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-chloro-1-[(1,4-dimethyl-1H-imidazol-5-yl)methyl]-, monohydrate (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 4 HCl


● 2 H₂O

RN 317847-04-4 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-chloro-1-[(2-chloro-1,4-dimethyl-1H-imidazol-5-yl)methyl]- (9CI) (CA INDEX NAME)




RN 317847-05-5 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-methyl-1-[(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)


● H₂O

RN 317847-02-2 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-chloro-1-[(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)




RN 317847-03-3 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-6-chloro-1-[(3-(2-ethoxyethoxy)-6-methyl-2-pyridinyl)methyl]-, tetrahydrochloride, dihydrate (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317847-06-6 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminopropyl)-4-piperidinyl]-1-[(trimethylpyrazinyl)methyl]-, tetrahydrochloride, trihydrate (9CI) (CA INDEX NAME)

● 3 H₂O

● 4 HCl

RN 317847-07-7 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(3-(2-chloroethoxy)-6-methyl-2-pyridinyl)methyl]-, trihydrochloride, dihydrate (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 3 HCl

● 2 H₂O

RN 317847-08-8 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(3-amino-2-pyridinyl)methyl]-, tetrahydrochloride, trihydrate (9CI) (CA INDEX NAME)




● 4 HCl

● 3 H₂O

RN 317847-11-3 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-6-chloro-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride, compd.


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 4 HCl

● 3 H₂O

RN 317847-14-6 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-7-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride, dihydrate (9CI) (CA INDEX NAME)



● 4 HCl


● 2 H₂O

RN 317847-15-7 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-6-bromo-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 1

CRN 317847-10-2
CMF C22 H29 Cl N6 O




CM 2

CRN 67-63-0
CMF C3 H8 O




RN 317847-12-4 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-amino-3-methylbutyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride, trihydrate (9CI) (CA INDEX NAME)




RN 317847-13-5 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride, trihydrate (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 4 HCl

RN 317847-16-8 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride, monohydrate (9CI) (CA INDEX NAME)




● 4 HCl


● H₂O

RN 317847-17-9 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-[(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317847-18-0 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-5-chloro-7-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride, tetrahydrate (9CI) (CA INDEX NAME)




● 4 HCl


● 4 H₂O

RN 317847-19-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-5-chloro-1-[(2,4-dimethyl-5-oxazolyl)methyl]-7-methyl- (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317847-20-4 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-5-chloro-1-[(2,5-dimethyl-4-oxazolyl)methyl]-7-methyl-, dihydrochloride, monohydrate (9CI) (CA INDEX NAME)




● 2 HCl

● H₂O

RN 317847-21-5 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-5-chloro-7-methyl-1-[(5-methyl-3-isoxazolyl)methyl]-, trihydrochloride, monohydrate (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 3 HCl


● H₂O

RN 317847-22-6 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-methyl-5-oxazolyl)methyl]-, monohydrate (9CI) (CA INDEX NAME)

● H₂O

RN 317847-23-7 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-methyl-5-oxazolyl)methyl]-, trihydrochloride, monohydrate (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 3 HCl


● H₂O

RN 317847-26-0 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(4-thiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 317847-27-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 3 HCl

RN 317847-28-2 CAPLUS
CN 2-Oxazolemethanol, 5-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-, tetrahydrochloride, dihydrate (9CI) (CA INDEX NAME)



● 4 HCl


● 2 H2O

RN 317847-29-3 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(3-methyl-5-isoxazolyl)methyl]-, trihydrochloride, monohydrate (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317847-32-8 CAPLUS
CN 4-Oxazolecarboxylic acid, 5-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 317847-33-9 CAPLUS
CN 1-Piperidineethanamine, 4-[[1-[[3-(2-(dimethylamino)ethoxy)-6-methyl-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 317847-35-1 CAPLUS
CN 1-Piperidineethanamine, 4-[[1-[[3-(2-(dimethylamino)ethoxy)-6-methyl-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




● 3 HCl

● H2O

RN 317847-31-7 CAPLUS
CN 2-Propanol, compd. with 4-[[1-[[2-(dimethylamino)-4-thiazolyl]methyl]-1H-benzimidazol-2-yl]methyl]-1-piperidineethanamine tetrahydrochloride (1:1), monohydrate (9CI) (CA INDEX NAME)

CH 1


CRN 317847-30-6
CMF C21 H30 N6 S




CH 2

CRN 67-63-0
CMF C3 H8 O


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317847-36-2 CAPLUS
CN 4-Piperidineamine, N-[[1-[[6-methyl-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 317847-85-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-methyl-5-oxazolyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 317847-94-2 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-methyl-5-oxazolyl)methyl]- (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 317847-86-2 317847-87-3 317847-88-4
317847-89-5 317847-90-8 317847-91-9
317847-92-0 317847-93-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of benzimidazoles as respiratory syncytial virus replication inhibitors)

RN 317847-86-2 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-amino-3-methylbutyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl


RN 317847-87-3 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-amino-3-methylbutyl)-4-piperidinyl]amino]-7-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-, tetrahydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 317847-90-8 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(6-methyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 317847-91-9 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-4-chloro-1-[(6-methyl-2-pyridinyl)methyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl


RN 317847-92-0 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-5,6-dimethyl-1-[(6-methyl-2-pyridinyl)methyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




● 4 HCl


RN 317847-88-4 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-chloro-1-[(1,4-dimethyl-1H-imidazol-5-yl)methyl]- (9CI) (CA INDEX NAME)



RN 317847-89-5 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-3-bromo-1-methyl-, ethyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



● 4 HCl


RN 317847-93-1 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(6-methyl-2-pyridinyl)methyl]-6-nitro-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl

IT 90519-14-5 317847-66-8 317847-67-9
317847-68-0 317847-69-1 317847-71-5
317847-73-7 317847-74-8 317847-75-9
317847-76-0 317847-77-1 317847-78-2
317847-79-3 317847-80-6 317847-83-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of benzimidazoles as respiratory syncytial virus replication inhibitors)


RN 90519-14-5 CAPLUS
CN 1H-Benzimidazol-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




4/11/2003

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 317847-66-8 CAPLUS
CN 1-Piperidineacetic acid, .alpha.-ethyl-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 317847-67-9 CAPLUS
CN 1,4-Dioxo-8-aza-spiro[4.5]decan-8-[[1-(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 317847-68-0 CAPLUS
CN 1H-Benzimidazol-2-amine, N-4-piperidinyl-1-[(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 317847-69-1 CAPLUS
CN 1-Piperidineethanol, 4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317847-75-9 CAPLUS
CN Carbamic acid, [2-[4-[[1-(1,5-dimethyl-1H-pyrrol-2-yl)methyl]-4-methyl-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317847-76-0 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-[[4-methyl-1-[3-(2-pyridinyl)propyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 317847-77-1 CAPLUS
CN 2-Butanone, 3-methyl-1-[4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)

Habte


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317847-71-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 6-[[2-(4-piperidinylamino)-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 317847-73-7 CAPLUS
CN Carbamic acid, [2-[4-[[1-(6-methyl-2-pyridinyl)methyl]-6-nitro-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317847-74-8 CAPLUS
CN 1-Piperidinepropanoic acid, .alpha.-[[1-(1,1-dimethylethoxy)carbonyl]amino]-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317847-78-2 CAPLUS
CN 2-Butanone, 1-[4-[[6-chloro-1-[(2-chloro-1,4-dimethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 317847-79-3 CAPLUS
CN 2-Butanone, 1-[4-[[1-[(2-chloro-1,4-dimethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 317847-80-6 CAPLUS
CN Carbamic acid, [2-[4-[[1-(6-methyl-3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

4/11/2003

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 317847-83-9 CAPLUS
CN 1-Piperidinebutanenitrile, 4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)




IT 317847-37-3P 317847-38-4P 317847-39-5P
317847-40-8P 317847-48-6P 317847-49-7P
317847-50-0P 317847-51-1P 317847-52-2P
317847-53-3P 317847-54-4P 317847-55-5P
317847-56-6P 317847-57-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzimidazoles as respiratory syncytial virus replication inhibitors)
RN 317847-37-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-(6-methyl-2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
(phenylmethyl)-4-piperidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 317847-48-6 CAPLUS
CN 1H-Benzimidazol-2-amine, N-1,4-dioxaspiro[4.5]dec-8-yl-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 317847-49-7 CAPLUS
CN Cyclohexanone, 4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 317847-50-0 CAPLUS
CN 1-Piperidineethanol, .beta.-ethyl-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)




L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317847-38-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-(6-methyl-3-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]-2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 317847-39-5 CAPLUS
CN 1H-Azepine-1-carboxylic acid, hexahydro-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 317847-40-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[(6-methyl-2-pyridinylmethyl)-2-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 317847-51-1 CAPLUS
CN 1H-Isindole-1,3(2H)-dione, 2-[2-[4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)



RN 317847-52-2 CAPLUS
CN 4-Piperidinone, 1-[[1-(6-methyl-2-pyridinylmethyl)-1H-benzimidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 317847-53-3 CAPLUS
CN 1,2-Ethanediamine, N'-[[1-[[1-(6-methyl-2-pyridinylmethyl)-1H-benzimidazol-2-yl]methyl]-4-piperidinyl]-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 317847-54-4 CAPLUS
CN 1-Piperidineacetoneitrile, .alpha.-methyl-4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]- (9CI) (CA INDEX NAME)


L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 317847-55-5 CAPLUS
CN 2-Butanone, 1-[4-[[1-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 317847-56-6 CAPLUS
CN 1H-Benzimidazol-2-amine, 4-methyl-1-[(6-methyl-2-pyridinyl)methyl]-N-[1-(oxiranylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 317847-57-7 CAPLUS
CN Ethanol, 2-[(phenylmethyl)[2-[4-[[1-(2-pyridinylmethyl)-1H-benzimidazol-2-yl]amino]-1-piperidinyl]ethyl]amino]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:259972 CAPLUS

DOCUMENT NUMBER: 132:293042

TITLE:

Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
Van Lengerich, Bernhard H.
General Mills, Inc., USA
PCT Int. Appl., 56 pp.
CODEN: PIXX02

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021504	A1	20000420	WO 1999-US20905	19991006
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HA, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2345815	AA	20000420	CA 1999-2345815	19991006
AU 9963872	A1	20000501	AU 1999-63872	19991006
EP 1119345	A1	20010801	EP 1999-951433	19991006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002527375	T2	20020827	JP 2000-575480	19991006
NO 200004784	A	20000925	NO 2000-4784	20000925

PRIORITY APPLN. INFO.:


US 1998-103700P	P	19981009
US 1998-109696P	P	19981124
US 1999-233443	A	19990120
US 1998-79060P	P	19980323
WO 1999-US4267	W	19990323
WO 1999-US20905	W	19991006

AB A liq. encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liq. plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liq. plasticizer and the encapsulation of the active encapsulant is accomplished at a low temp. and under low shear conditions. The active component is encapsulated and/or embedded in the plasticizable matrix component or material in a continuous process to produce discrete, solid particles. The liq. content of the liq. encapsulant component provides substantially all or completely all of the liq. plasticizer needed to plasticize the matrix component to obtain a formable, extrudable, cuttable, mixt. or dough. Removal of liq. plasticizer prior to extrusion is not needed to adjust the viscosity of the mixt. for formability. Release of an active component from the matrix may be delayed or controlled over time so that the active component is delivered when and where it is needed to perform its intended function. Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant.

IT 68844-77-9, Astemizole

Habe

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

RN 68844-77-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

4/11/2003

L5 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:293427 CAPLUS
DOCUMENT NUMBER: 129:8597
TITLE: Embedding and encapsulation of controlled release particles
INVENTOR(S): Van Lengerich, Bernhard H.
PATENT ASSIGNEE(S): Van Lengerich, Bernhard H., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: F1XXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818610	A1	19980507	WO 1997-0518984	19971027
W: AU, CA, JP, NO, PL, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9749915	A1	19980522	AU 1997-49915	19971027
AU 744156	B2	20020214		
EP 935523	A1	19990818	EP 1997-912825	19971027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002511777	T2	20020416	JP 1998-520558	19971027
NO 9902036	A	19990428	NO 1999-2036	19990428

PRIORITY APPLN. INFO.:
US 1996-290389 P 19961028
US 1997-52717P P 19970716
WO 1997-0518984 W 19971027

AB Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The addnl. component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass. The plasticizer content is substantially reduced and the temp. of the plasticized mass is substantially reduced prior to admixing the plasticized mass with the encapsulant to avoid substantial destruction of the encapsulant and to obtain a formable, extrudable mixt. The mixt. is extruded through a die without substantial or essentially no expansion and cut into discrete, relatively dense particles. Release properties may also be controlled by precoating the encapsulant and/or coating the extruded particles with a film-forming component. An example of encapsulation of acetylcysteine is given using starch, polyethylene, glycerol monostearate, and vegetable oil.

IT 68844-77-9, Astemizole
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

L5 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 68844-77-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/888,840

Page 35

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

71.01

219.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-9.77

-9.77

STN INTERNATIONAL LOGOFF AT 13:19:30 ON 15 APR 2003

Habte

4/11/2003